RxDoctor Payments Data

Gregory Todd, DO

Family Medicine · Allentown, PANPI 1376590661

Payments from drug & device makers

$999in general payments, 2019–2025

Across 12 payments — averaging $83.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$125
  • Esperion Therapeutics, Inc.$125
  • Merck$125
  • Alkermes, Inc.$125
  • Boehringer Ingelheim$125
  • GSK$115
  • plus $261 from 5 others

What the payments were for

  • Food & beverage$999100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$999 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$236,381
Medicare patients
431
Services billed
3,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban133$121,463
JardianceEmpagliflozin124$120,377
OzempicSemaglutide48$75,403
XareltoRivaroxaban75$74,710
MounjaroTirzepatide57$57,705
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$56,694
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$30,358
FarxigaDapagliflozin Propanediol21$30,082
Inderal LaPropranolol Hcl12$29,199
LinzessLinaclotide36$28,214
Tresiba Flextouch U-100Insulin Degludec27$26,638
TradjentaLinagliptin24$26,632
MyrbetriqMirabegron49$25,840
TrulicityDulaglutide13$24,852
JanuviaSitagliptin Phosphate13$19,749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$125$147,009148 claims
PfizerEliquis$32$121,463133 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$115$93,772110 claims
Novo NordiskOzempic$92$75,40348 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$106$46,43956 claims
MerckJanuvia, Janumet$125$33,89326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →